MwanzoPRENW • NASDAQ
add
Prenetics
$ 0.0098
Kabla ya soko:(2.04%)+0.00020
$ 0.010
Imefungwa: 31 Jan, 20:00:00 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 0.0083
Bei za mwaka
$ 0.0042 - $ 0.021
Thamani ya kampuni katika soko
64.14M USD
Wastani wa hisa zilizouzwa
elfu 28.50
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 7.78M | 59.86% |
Matumizi ya uendeshaji wa biashara | 15.76M | 2.99% |
Mapato halisi | -10.67M | 21.36% |
Kiwango cha faida halisi | -137.21 | 50.80% |
Mapato kwa kila hisa | — | — |
EBITDA | -10.71M | 14.43% |
Asilimia ya kodi ya mapato | 0.62% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 48.69M | -45.29% |
Jumla ya mali | 235.77M | -14.71% |
Jumla ya dhima | 55.67M | 16.88% |
Jumla ya hisa | 180.10M | — |
hisa zilizosalia | 12.72M | — |
Uwiano wa bei na thamani | 0.00 | — |
Faida inayotokana na mali | -12.59% | — |
Faida inayotokana mtaji | -15.54% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -10.67M | 21.36% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Ilianzishwa
2014
Tovuti
Wafanyakazi
322